Background and Aims: Macrophages are a promising therapeutic target for intestinal mucosal repair. MiR-146b appears to control macrophage activation and cell proliferation. Methods: By loading miR-146b mimic on mannose-modified trimethyl chitosan [MTC]-conjugated nanoparticles [NPs] [MTC-miR146b], a molecular targeted immunotherapeutic approach was developed to selectively target intestinal macrophages for mucosal regeneration and tumourigenesis in mouse models. Results: We first confirmed that miR-146b expression was significantly enhanced during mucosal regeneration in a murine colitis model. Moreover， after mucosal damage, MTC-miR146b mimictreated wild-type mice had dramatically restored body weight and mucosal barrier function compared with MTC-NC treated mice. Strikingly, MTC-miR146b mimic oral administration protected miR-146b-deficient mice from dextran sodium sulphate [DSS] injury and the colitisassociated cancer process. Mechanistically, miR-146b strongly inhibited M1 macrophage activation by suppressing the Toll-like receptor 4 [TLR4] signalling pathway, resulting in the repression of the induction of pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β. More importantly, miR-146b overexpression in bone marrow-derived macrophages [BMDMs] in M1 differentiation conditions induced a phenotype similar to M2 macrophages and improved the proliferation of co-cultured colonic epithelial cells via STAT3-dependent IL-10 production. Conclusions: MTC-miR146b should be regarded as an effective candidate for oral delivery and could improve the efficacy of immunotherapies for ulcerative colitis and colitis-associated cancer.
Introduction
Ulcerative colitis [UC] is a subcategory of inflammatory bowel disease [IBD] with a high risk of colitis-associated cancer [CAC] . 1 It manifests two crucial pathophysiological features: dysregulation of the innate immune system, and impaired mucosal repair. 2 The combination of both dysfunctions can lead to devastating clinical consequences. Although immunosuppressive drugs, including corticosteroids, immunomodulators and monoclonal antibodies, are already regularly used in the clinic, UC remains a challenge due to the limited arsenal of therapies available. Addressing both pathophysiological components is currently regarded as a key therapeutic strategy for UC. 3, 4 An intricate repair process is triggered by a series of events involving the epithelium itself as well as immune cells, which are recruited to wound sites within several minutes of injury. 5 Macrophages derived from peripheral blood monocytes constitute an essential component of innate immune responses. 6 They display remarkable plasticity and can acquire distinct functional phenotypes in response to environmental cues [e.g., microbial products and cytokine signals]. 7, 8 Two of the best-characterised phenotypes are classically activated macrophages [M1] and alternatively activated macrophages [M2] . The M1 phenotype that mediates host defence is characterised by an enhanced microbicidal capacity and production of high levels of pro-inflammatory cytokines [TNF-α, IL-1, IL-6, and IL -23] . In contrast, M2 macrophages are considered to be involved in tissue repair and tumour progression, and they secrete components of the extracellular matrix and express high levels of anti-inflammatory cytokines [IL-4, IL-10, and IL-13]. [9] [10] [11] Macrophage-mediated wound repair involves a progression in cell phenotype from M1 dominance in the early stage to M2 dominance in the later stage. 12 Previous studies have reported the phenotypic transition of macrophages in skeletal muscle and skin repair 10, 13 ; however, limited data are available for the M1/M2 switch during intestinal repair.
MicroRNAs [miRNAs] are small, endogenous non-coding RNA sequences that primarily function by interacting with the 3′ UTRs of gene transcripts to control the transcription of genes. 14, 15 Expression profiling of 200 miRNAs in human monocytes revealed that three miRNA genes [miR-146a/b, miR-132, and miR-155] are significantly upregulated in response to lipopolysaccharide [LPS] . 16 Enhanced expression of miR-146b in human monocytes via an IL-10 dependent loop plays an anti-inflammatory role by directly targeting the TLR4 signalling pathway. 17 Interestingly, our previous study found that IL-10 dependent expression of miR-146b targeted IRF5 to inhibit M1 macrophage activation, and miR-146b mimic obviously ameliorated colitis development in vivo, indicating the crucial role of miR-146b in treatment of intestinal inflammation by suppressing M1 macrophage orientation. 18, 19 Among systemic administration routes, oral delivery is one of the most appropriate means of administration. However, the oral delivery of miRNAs faces multiple challenges in moving molecules from the gastrointestinal tract to the intracellular space of target cells.
Nanotechnology is a promising approach that provides safer and more efficient solutions than conventional drug delivery. 20 Several engineered 'smart' nanomaterials have been constructed as carriers for clinical therapeutic and diagnostic agents. 21, 22 Here, we applied a molecular targeted immunotherapeutic strategy by using dualtargeting NPs to deliver miR-146b to intestinal macrophages. We speculated that miR-146b, which clearly inhibits M1 macrophage activation, would be an ideal target for our nanoparticle. Then, mannose-modified trimethyl chitosan [MTC] , which is taken up by macrophages via mannose receptor-mediated endocytosis, was selected as another targeting unit. MTC was linked with miR-146b mimic by ionic cross-linking to form a dual-targeting NP, designated as MTC-miR146b. MTC-NPs can successfully overcome various extracellular and intracellular barriers and efficiently target intestinal macrophages, causing M1 macrophage transition to M2 type to inhibit the inflammatory response and promote mucosal regeneration. Therefore, with high biocompatibility, we expect that these gene-specific, dual-targeting NPs will offer a novel therapeutic strategy for ulcerative colitis. 
Materials and Methods

Materials and antibodies
Preparation of MTC-based nanoparticles
Mannose-modified trimethyl chitosan [MTC] was synthesised as follows. First, the modification of trimethyl chitosan with mannose was performed by gently stirring trimethyl chitosan in water [1%, w/v] and mannopyranosylphenyl isothiocyanate in dimethyl sulphoxide [DMSO; 1%, w/v] at a mole ratio of 1:50 at pH 9.0 for 12 h. Second, MTC [10 kDa] was obtained by dialysis with distilled water and lyophilisation; its structure was determined by 1H NMR [Jeol, Japan] .
miRNA-loaded nanocomplexes were fabricated by ionic cross-linking. The sequence of the FAM miR-146b mimic was UGAGAACUGAAUUCCAUAGGCU, and the sequence of the negative control was UUCUCCGAACGUGUCACGUTT; mice and humans share the same miR-146b sequence. Briefly, miRNAs [0.1 mg/mL] and branched PEI were dissolved in diethyl pyrocarbonate [DEPC] water and mixed at the miRNA/PEI mole ratio of 1:10. Subsequently, the mixture was dropwise added into MTC solution [1.5 mg/mL, dissolved in DEPC water] under stirring, and was incubated at 37°C for 60 min to form nanocomplexes. The resultant MTC/miR-146b mimic complex is abbreviated as MTC-miR146b, and the MTC/negative control complex is abbreviated as MTC-NC.
Characterisation of MTC-based nanoparticles
Nanocomplex size and zeta potential were determined with a Malvern laser particle size analyser [Mastersizer 3000E]. The morphology of the nanocomplexes in purified water was determined by using a Hitachi H600 type transmission electron microscope.
Evaluation of miRNA integrity and encapsulation efficiency
For miRNA integrity evaluation, the nanocomplexes were added into phosphate-buffered saline [PBS; pH = 7.4] or HCl solutions [pH = 2.0] for 2 h; then, heparin [1000 U/mL] was added to dissociate the miRNAs after modulating pH and heating at 80°C for 5 min. miRNA integrity was subsequently assessed by 4% [w/v] agarose gel electrophoresis at 60 V for 45 min.
The miRNA encapsulation efficiency [EE] was determined by ultra-filtering the nanoparticles entrapping FAM-miRNA, using centrifugal filter devices [100 000 NMWL, Millipore, MA]. After thorough ultra-filtration with DEPC water, unencapsulated FAMmiRNAs were collected and quantified using a calibration line obtained with standard lead FAM-miRNA solutions. The fluorescence of FAM-miRNAs was determined with the spectrofluorometer using excitation and emission wavelengths of 495 and 525 nm, respectively. The miRNA EE was calculated using the formula: [Mi-MU]/Mi × 100%. MU and Mi were defined as the mass of the unencapsulated miRNAs and the initially added miRNAs, respectively.
In vivo biodistribution evaluation
For in vivo imaging, the C57BL/6 mice were orally administered 20 µg/kg MTC-miR146b. Fluorescent FAM-labelled nanocomplexes were used for measuring in vivo uptake. The mice were sacrificed at 0, 6, 12, 24, and 48 h after administration, and the major organs including the heart, liver, kidney, spleen, and gut were harvested and imaged with a small animal in vivo fluorescence imaging system [In-Vivo Imaging System FX Pro, Bruker, Billerica, USA].
Mouse work
miR-146b deficient mice [ages 6-8 weeks, weight 18-20 g] were generated with CRISPR/Cas9 by Applied Stem Cell. C57BL/6 mice [ages 6-8 weeks, weight 18-20 g] were purchased from the Medical Experimental Animal Centre of Southern Medical University. All experiments were performed with the approval of the Animal Experimentation Committee of Southern Medical University [2016023] and in accordance with the institutional regulations. In the treatment group, mice were orally administered 20 µg/kg MTC-miR146b twice a week. In the control group, mice were given MTC-NC orally at the same dose for 1 week.
For DSS-induced colitis, mice received water with 3% DSS [MW 40000-50000, MP Biomedicals] for 5-7 days, followed by normal drinking water. During the DSS treatment, a disease activity index [DAI] was determined by recording standard parameters including body weight loss [score 0, no weight loss; score 1, weight loss within 5%; score 2, within 5-10%; score 3, within 11-15%; and score 4, more than 15%], bloody stool [score 0, normal; score 2, stool Haemoccult positivity; and score 4, gross bleeding], and stool consistency [score 0, normal; score 2, loose; and score 4, diarrhoea]. The final DAI was equal to one-third of the combined score, resulting in a total scoring range of 0-12. 23 To generate colitis-associated colorectal carcinoma, mice were intraperitoneally injected with 10 mg/kg body weight azoxymethane [AOM, Sigma-Aldrich Corp.]. One week later, mice were given 3% DSS in distilled water for 7 days followed by 14 days of normal drinking water as previously described. 24 This cycle was repeated three times. Mice were sacrificed after the third cycle ended. 
Western blot
Equal amounts of protein samples were run on a 10% SDS-PAGE gel and blotted onto a polyvinylidene difluoride membrane [Bio-Rad]. Protein blots were incubated with the primary antibody at 4°C overnight and then with the appropriate secondary antibody for 1-2 h at room temperature, followed by detection with an enhanced chemiluminescence detection system.
Histochemistry, immunohistochemistry, and immunofluorescence
For immunohistochemistry, 5-μm thick deparaffinised sections were prepared by quenching the endogenous peroxidases and performing antigen retrieval and subsequent blocking steps. Slices were incubated with the appropriate primary antibodies at 4°C overnight, followed by incubation with a biotinylated secondary antibody for 1-2 h at room temperature. The immunosignal was detected with a DAB kit. Histological scoring of inflammation and identification of tumours were independently performed by two senior pathologists.
For immunofluorescence, colon specimens from mice were collected and immediately embedded in Optimum Cutting Temperature compound, cryosectioned, and fixed with pre-chilled acetone for 20 min at room temperature. The sections were incubated with primary antibody overnight at 4°C. After three rounds of PBS washing, tissues were incubated with fluorescent secondary antibodies for 1 h and counterstained with DAPI. Images were acquired using fluorescence microscopy [Olympus, Japan].
Cell staining and flow cytometry analysis
LPCs were isolated from the colons of the AOM/DSS-induced colitis mice. Cells were stained with anti-mouse MHCII-PE, anti-CD206-APC, and anti-mouse F4/80-PE-Cy 5.5 antibodies and fixed with IC Fixation Buffer [eBioscience]. Flow cytometry was performed on a FACS AriaIII [BD Biosciences] and captured data were subsequently analysed using FlowJo. 
In vitro wound healing assays
BrdU labelling assays and histological analysis
Mice received an intraperitoneal injection of 50 mg/kg BrdU [5-bromo-2′-deoxyuridine, Sigma-Aldrich Corp.] 24 h before sacrifice. Their colons were collected for paraffin embedding, sectioning, and anti-BrdU antibody immunohistochemical staining. In each colon, histological scores were determined from 3-5 independent fields by combined scoring colonic epithelial damage [ranking 0-6; 0, normal; 1, hyperproliferation and irregular crypts; 2, mild to moderate crypt loss [10-50%]; 3, severe crypt loss [50-90%]; 4, complete crypt loss; 5, small-to medium-sized ulcer; 6, large ulcer], infiltration with inflammatory cells for mucosa [0, normal; 1, mild; 2, modest; 3, severe], submucosa [0, normal; 1, mild to modest; 2, severe], and muscle/serosa [0, normal; 1, moderate to severe]. Scores for epithelial damage and inflammatory cell infiltration were added. 25, 26 Immunoreactivity was assessed from immunoreactive scores [IRSs] according to positive area [score 1, <25%; score 2, 25-50%; score 3, 50-75%; score 4, >75% of the cell population in the biopsy specimen staining positive] and positive degree [score 0, negative; score 1, mild positive; score 2, moderate positive; score 3, strong positive]. Scores for positive area and degree were multiplied, resulting in a total scoring range of 0-12.
Statistics
Results were expressed as the mean ± standard error of the mean [SEM] . SPSS 21.0 software [SPSS Inc., Chicago, IL] was used for analysis. Significance was determined using Student's t test, one-way or two-way analysis of variance [ANOVA], as appropriate, for various comparisons. Statistical significance was defined as a p=value <0.05.
Results
miR-146b expression was upregulated during mucosal repair in a murine colitis model
As previously reported, miR-146b expression in the liver was elevated after Schistosoma japonicum infection and was crucial to the resolution of hepatic schistosomiasis. 27 To investigate the role of miR-146b during intestinal inflammation and regeneration, we used the well-established DSS-induced colitis and repair mouse model. In homeostasis, PCNA-positive [PCNA + ] epithelial cells were regularly located in crypt bases. With 5 successive days of 3% DSS administration, colonic crypts in the mice largely disappeared as extensive inflammatory cell infiltrates appeared in the mucosa. However, by 3 days after DSS removal, the mucosal ulcers were highly reduced, and PCNA + epithelial cells extended along the entire crypt axis. The crypt structures and epithelial cell proliferation rates were close to normal 5 days after DSS withdrawal [ Figure 1A ].
In this model, we examined the expression of miR-146b in mucosal samples from mice at various time points. As shown in Figure 1B , the expression of miR-146b was significantly increased by Day 3 after DSS removal compared with that on Day 0 post-DSS; this was followed by a decrease at Day 5 post-DSS. It is well acknowledged that the roles of miRNAs are cell-type specific; thus, we isolated different types of colon cells from the Day 0 and Day 3 post-DSS colons and examined miR-146b expression. We found that the abundance of miR-146b in lamina propria cells [LPCs] was significantly higher than that in epithelial cells. At 3 days post-DSS, there was a dramatic enhancement in miR-146b expression in LPCs compared with the expression levels in LPCs at Day 0 post-DSS [ Figure 1C ]. In addition, M2 macrophage-associated cytokines, including IL-10 and IL-13, strongly increased at Day 3 post-DSS. However, the level of the M1 macrophage-related cytokine IL-1β peaked at Day 5 and decreased after DSS withdrawal [ Figure 1B ], which suggested that the macrophage phenotype was altered in colonic mucosa during inflammation and regeneration. Therefore, miR-146b in LPCs may act as an important mediator during macrophage phenotype transition and mucosal closure during intestinal regeneration.
Characteristics of MTC-based nanoparticles
To further validate the crucial role of miR-146b in macrophage polarisation during mucosal repair, mannose-modified trimethyl chitosan [MTC] conjugated to miR-146b nanoparticles [NPs] [MTCmiR146b] were produced via ionic cross-linking and selectively targeted to gut-associated macrophages after oral delivery. 28, 29 The thiourea reaction was performed between the isothiocyanate group of mannopyranosylphenyl isothiocyanate and the amine groups of trimethyl chitosan. In the 1H NMR spectrum of MTC, signals at 7.0~7.4 ppm corresponded to the protons on the benzene group of mannopyranosylphenyl isothiocyanate and confirmed the conjugation of mannose to the backbone of trimethyl chitosan (acetyl protons [2.2 ppm] of chitosan) [ Figure 2A ]. Particle size analyses of MTC-NC and MTC-miR146b NPs showed that the size of MTC-NC was approximately 209 nm, and the particle size of MTC-miR146b was 213.6 nm [ Figure 2C ]. The zeta potential of MTC-NC was approximately +25.6 mV and that of MTC-miR146b was +28.3 mV. As shown in Figure 2B , miR-146b was fully entrapped in the MTCNPs. Additionally, the miRNA EE of MTC-NC and MTC-miR146b were approximately 96.1% and 95%, respectively, indicating that miRNAs were efficiently conjugated with MTC [ Table 1 ].
Next, we examined the cellular uptake and cytotoxicity of MTCmiR146b nanoparticles in bone marrow-derived macrophages [BMDMs] . Fluorescence microscopy analysis showed that BMDMs took up FAM-labelled MTC-miR146b in a concentration-dependent manner [ Figure 2E ]. No significant differences in cell viability were observed between nanocomplex-treated cells and untreated cells [ Figure 2D ]. Furthermore, orally delivered MTC-based NPs exhibited potent gene upregulation in the colonic mucosa of mice in vivo [ Supplementary Figure 1 , available as Supplementary data at ECCO-JCC online], and immunofluorescence in the colon of DSSinduced colitis mice showed that MTC-based NPs were specifically detected in F4/80 + intestinal macrophages [ Figure 2F ]. Meanwhile, in vivo imaging of mice after MTC-miR146b oral administration exhibited that fluorescent FAM accumulated in the intestinal tract, the fluorescence intensity in the intestinal tract peaked at 6 h after gavage, followed by decreases at 12 h and 24 h, and a moderate fluorescent signal was still detected after 48 h [ Figure 2G ]. Thus, these MTC-based NPs, with high encapsulation efficacy and longterm retention, could selectively target to intestinal macrophages without cytotoxicity and may act as 'smart' carriers in intestinal disease research.
MTC-miR146b nanoparticles promoted mucosal regeneration in the DSS-induced colitis model
Based on the characteristics of the MTC-miR146b nanoparticles, we next explored their role in DSS-induced inflammation and regeneration. We first investigated the toxicity of NPs in vivo by oral delivery of MTC-NC and MTC-miR146b nanocomplexes to normal mice.
No significant changes were observed in either the crypt structures or the production of inflammatory cytokines in colonic mucosa between the two groups 28 days after administration [ Supplementary  Figure 2A and B available as Supplementary data at ECCO-JCC online]. Notably, we did not observe the death of any mice after treatment with the nanocomplexes for 12 weeks.
Next, we assessed the susceptibility of nanocomplex-treated mice to acute DSS-induced colitis. On average, no significant changes in body weight were observed during the 5 days of DSS treatment. Histological assessments showed that both MTC-NC and MTCmiR146b treated mice exhibited catastrophic damage to the colonic mucosa and extensive inflammatory cell infiltration at Day 5 of DSS treatment [ Figure 3C and G]. However, MTC-miR146b treated mice rapidly regained body weight after DSS withdrawal, whereas mice treated with MTC-NC showed delayed recovery [ Figure 3A ]. In addition, 3 days after DSS removal, the MTC-miR146b treated mice had a colon length 1.5 cm longer than that of the MTC-NC treated mice [ Figure 3B and D]. The epithelial structures and gut barrier integrity in MTC-miR146b treated mice were largely restored compared with [B] mRNA expression levels of miR-146b and cytokines were detected at the indicated times by real-time PCR. Data represent the mean ± SEM; *p <0.05, **p <0.01, ****p <0.0001. [C] . mRNA expression levels of miR-146b in the mucosa, lamina propria cells or epithelial cells from C57BL/6 mice at Day 0 and after 5 days of 3% DSS followed by 3 days of normal drinking water. Data represent the mean ± SEM. ***p <0.001. DSS, dextran sodium sulphate; H&E, haematoxylin and eosin; SEM, standard error of the mean; PCR, polymerase chain reaction.
MTC-NC treated mice [ Figure 3E ]. More importantly, we found that the ameliorative inflammatory response in MTC-miR146b treated mice was accompanied by significantly decreased expression of M1 macrophage mRNAs encoding iNOS, TNF-α, and IL-1β, and obviously upregulated M2 phenotype signature genes, CD206 and Arg-1, in the colonic mucosa of these mice [ Figure 3F ]. This suggested that the MTC-miR146b treatment facilitated the development of the M2 phenotype of intestinal macrophages during mucosal repair. Moreover, previous reports have confirmed that miR-146b was a negative regulator of the TLR4 signalling pathway. 17 In our study, we also observed that the expression levels of MyD88 and IRAK1 in colonic crypts of MTC-miR146b treated mice were clearly repressed compared with their expression levels in MTC-NC treated mice [ Figure 3H ]. Collectively the data show that oral delivery of MTCmiR146b nanoparticles could resolve inflammatory response and promote epithelial regeneration after DSS-induced colitis. The macrophage-specific MTC-miR146b caused a cell phenotype transition that may play a pivotal role during this progression.
miR-146b promoted epithelial cell proliferation via STAT3-dependent IL-10 production
Previously, studies have determined that miR146b suppressed M1 macrophage activation by targeting the TLR4 signalling pathway, and that miR146b regulated the differentiation of macrophages into M2 phenotype cells. 27 To further investigate the function of miR146b in vitro, we then treated BM cells with M-CSF only cells [ Figure 4A ]. Meanwhile, the mRNA levels of the M1 signature genes CD86 and TNF-α were dramatically elevated in the M1 and NC-transfected M1 cells, but transfection of miR-146b into the M1 cells attenuated these levels [ Figure 4B ]. Moreover, we observed that the mRNA level of miR-146b was significantly enhanced in the M2 cells [ Figure 4B ]. These data indicated that miR-146b treated macrophages shared similar biological functions with M2 macrophages, and miR-146b inhibited M1 macrophage orientation by suppressing the TLR4 signalling pathway. The mucosal regeneration process represents a wound healing reaction, that is proliferation of epithelial cells is triggered by the inflammatory cytokines and growth factors, which are secreted by recruited inflammatory cells. Among the produced inflammatory cytokines, IL-10 is an important regulator of mucosal homeostasis and repair 30 ; it is well documented that M2 macrophages can secrete high amounts of IL-10. Because the miR-146b treated cells manifested an M2-like phenotype, we wondered whether miR-146b triggered mucosal regeneration by IL-10 induction. Using in vitro wound healing assays, we co-cultured FHC cells with miR-146b-or NC-transfected, LPS/IFN-γ treated [M1] macrophages and found that the miR-146b mimic-transfected M1 cells exhibited enhanced wound closure compared with the NC-transfected M1 cells. However, administration of IL-10-neutralising antibodies to the miR146b mimic-transfected M1 cells reversed this effect [ Figure 4D ]. Furthermore, as the transcriptional activator STAT3 plays essential roles in regulation of epithelial cell survival and proliferation, and is generally activated by the IL-10 family of cytokines, [31] [32] [33] we assumed that IL-10 secreted by M2 or M2-like macrophages promoted epithelial cell proliferation in a STAT3-dependent manner. In our study, treatment with recombinant IL-10 promoted wound closure in FHC cells, whereas adding the STAT3 inhibitor Stattic clearly inhibited epithelial cell proliferation [ Figure 4D ]. In addition, Stattic reversed the IL-10-induced upregulation of CyclinD1 and C-Myc [ Figure 4C ]. Collectively, miR-146b regulated the macrophages to differentiate into M2-like phenotype cells to promote epithelial cell proliferation through STAT3-dependent IL-10 production. 
MTC-miR146b nanoparticles ameliorated colitis development in miR-146b -/-mice
To further investigate the function of miR-146b in the control of mucosal regeneration, we generated miR-146b deficient [miR-146b
-/-mice exhibited more susceptibility to intestinal colitis. Previous data showed that delivery of MTC-NC or MTC-miR146b NPs did not cause visible alterations in the epithelial structures or inflammatory cytokine production in normal mice. To examine whether application of MTC-miR146b nanoparticles rendered mice more resistant to chemically induced injury, we applied NPs to miR-146b -/-mice followed by a classic CAC procedure. At the beginning of the CAC protocol, histological assessments demonstrated that MTC-miR146b treated miR-146b -/-mice exhibited better structural integrity and ameliorative inflammatory response than untreated mice. In contrast, the MTC-NC treated mice presented with catastrophic crypt loss and widespread inflammatory cell infiltration in the mucosa [ Figure 5A ]. Moreover, the expression of the M1 macrophage signatures CD86 and CCR7 in the colonic mucosa of mice was significantly decreased after MTC-miR146b treatment, accompanied by downregulated mRNA levels of proinflammatory cytokines IFN-γ, IL-1β, and IL-6 [ Figure 5B ]. More importantly, expression of the M2 macrophage signature Arg-1 was clearly enhanced after MTC-miR146b application; furthermore, the induction of IL-10 was elevated [ Figure 5B and C]. The expression levels of STAT3 and Ki67 in MTC-miR146b-treated mice were also higher than those in the MTC-NC treated mice [ Figure 5C ]. Therefore, we concluded that miR-146b regulated the innate macrophage transition into M2-like cells and played a strong protective role during the mucosal damage in the acute inflammatory process of CAC.
3.6. MTC-miR146b nanoparticles suppressed the development of colitis-associated carcinoma in miR-146b -/-mice
After the third cycle of the CAC regimen was completed, we had successfully created a colitis-associated carcinoma model and observed palpable tumours near the rectum of mice [ Figure 6A ]. Interestingly, 
miR-146b
-/-mice treated with MTC-miR146b developed significantly smaller tumour numbers and tumour areas than MTC-NC treated mice [ Figure 6B and C]. In addition, histological assessments showed that the colonic mucosa in MTC-miR146b treated mice presented with low-grade dysplasia, but the tumours of MTC-NC treated mice were identified as high-grade dysplasia [ Figure 6D ]. Furthermore, LPCs were isolated from the colons of both groups and analysed by flow cytometry, which indicated that MHCII + F4/80 + cells were decreased in the MTC-miR146b treated mice, but CD206 + F4/80 + cells were increased in the MTC-NC treated mice [ Figure 6E ]. Strikingly, in the process of acute mucosal injury, MTCmiR146b treated mice exhibited more intact epithelium structures, concomitant with upregulation of Arg-1, whereas during the CAC, Arg-1 expression in the colonic mucosa of MTC-miR146b treated mice was lower than that in control mice [ Figure 6F ]. This finding suggested that in the background of azoxymethane [AOM]-induced missense mutations, chronic inflammation impaired the epithelial micro-environment and macrophage functions, resulting in the development of inflammation-induced cancer. Arg-1 expressing macrophages around the neoplastic epithelial cells mainly presented with the tumour-associated macrophage [TAM] phenotype 34 rather than the protective signature seen in regeneration. A concomitant alteration was also observed in STAT3 [ Figure 6F ]. Therefore, miR-146b suppressed the development of CAC by attenuating the 'the second hit' of cancer.
Discussion
Ulcerative colitis [UC] is a chronic inflammatory bowel disease [IBD] characterised by dysregulation of the immune system and impaired epithelial regeneration. 2 Limited therapies are available at present, which makes UC management challenging for clinicians. In our study, we applied a molecular targeted immunotherapeutic strategy using dual-targeting NPs [MTC-miR146b] that delivered miR-146b to intestinal macrophages. By oral administration, the MTC-miR146b NPs inhibited M1 macrophage activation and pro-inflammatory cytokine induction, to promote the mucosal repair and suppress the development of colitis-associated carcinoma. We concluded that miR-146b is a critical regulator in the control of intestinal immune function and epithelial regeneration; the dualtargeting MTC-miR146b NPs can be selected as 'smart' carriers for UC treatment.
Macrophages are key cells of the innate immune system, whose function varies during the development of ulcerative colitis by differentiating into various phenotypes. [35] [36] [37] Classically activated M1 cells are involved in initiating and maintaining inflammation, and alternatively activated M2 or M2-like cells are associated with the resolution of inflammation. 11, 38 We speculated that macrophages with a moderately more M2 than M1 phenotype will be beneficial to tissue repair after mucosal damage. In our study, we observed that the predominant production of cytokines in mouse colonic mucosa converted from M1-associated cytokines in colitis to M2-related cytokines in the subsequent regeneration process. miR-146b, which is crucial to intestinal macrophage phenotype, was sharply upregulated during mucosal repair after DSS-induced injury, suggesting that miR-146b is closely associated with M2 macrophage activation. Therefore, a therapy designed to dually target macrophages and miR-146b was selected to treat colitis. Nanoparticles [NPs] that exhibit the desired structural stability and effective repression of enzymatic degradation have been extensively studied for drug delivery. 20, 21, 39 Mannose-modified trimethyl chitosan [MTC]-conjugated NPs could overcome extracellular and intracellular barriers and selectively target macrophages by ligandreceptor recognition. 40 As reported, MTC-NPs conjugated with TNF-α exhibited higher efficiency of gene silencing in macrophages than Lipofectamine2000, and protected mice from inflammationinduced liver injury. 29 In our study, by loading an miR-146b mimic on MTC-NPs, we observed that MTC-miR146b strongly bound to intestinal tract macrophages, but poorly bound to the liver and other organs following oral administration. Compared with MTC-NC treatment, the oral administration of MTC-miR146b in mice significantly inhibited the intestinal inflammatory response and promoted epithelial regeneration after DSS-induced colitis, concomitant with downregulation of M1 macrophage mRNAs encoding iNOS, TNF-α, and IL-1β. More importantly, M2 signatures were clearly elevated after MTC-miR146b treatment. Therefore, miR146b could be an important mediator in the regulation of macrophage phenotype transition, a function that is essential during mucosal repair after colitis.
Several signalling pathways are involved in the regulation of macrophage phenotype transitions, such as IRF5, 18 STAT1, and SOCS1/2 for M1 activation and STAT3, STAT6, C/EBPβ, and IRF4 for M2 polarisation. 41 miR-146b has been implicated as a negative regulator controlling M1 macrophage activation at the level of post-transcriptional suppression. 42 miR-146b repressed the TLR4 signalling pathway in human monocytes by targeting three key downstream molecules MyD88, IRAK1, and TRAF6. 17, 43, 44 IL-10 dependent miR-146b could target IRF5 to inhibit M1 macrophage activation. 19 In addition, Th2 cytokines [IL-4, IL-10, and IL-13] were found to inhibit the differentiation of macrophages into the M1 type via induction of miR-146b by targeting STAT1. 27 In our study, we found that miR-146b transfection attenuated the upregulation of the TLR4 signalling pathway-associated targets MyD88 and IRAK1 in M1 macrophages, as well as the M1 signatures, suggesting that miR-146b repressed the M1 macrophage orientation by targeting the TLR4 signalling pathway. miR-146b administration could also inhibit the induction of pro-inflammatory cytokines after mucosal damage, resulting in a relatively increased proportion of anti-inflammatory cytokines such as IL-10, IL-4, and IL-13 in the mucosal micro-environment. These anti-inflammatory cytokines could induce macrophages into M2 polarisation, and account for the miR-146b treated macrophages having a phenotype similar to M2 macrophages. In addition, overexpression of miR-146a or miR-155 in macrophages resulted in an M2 phenotype by upregulation of c/EBPβ, a signature molecule in M2 macrophages which regulates Arg-1. 41, 45 Further studies could focus on the mechanisms by which miR-146b regulates M2 macrophage polarisation.
The mucosal repair process represents a complicated physiological reaction that involves multiple factors, including epithelial cells, growth factors, and inflammatory cells. Our previous work has studied the molecular mechanism of YAP-driven mucosal repair in epithelial cells. 46 Understanding how the inflammatory cells act on the epithelial cells was preliminarily probed in this research. Macrophage-derived IL-10 caused the activation of epithelial CREB and the subsequent secretion of pro-repair WISP-1 to promote epithelial cell proliferation and wound healing. 33 IL-22, a member of the IL-10 family, can be induced by innate lymphoid cells [ILCs] after intestinal injury, and can promote the growth of murine small intestine organoids and mucosal regeneration in a STAT3-dependent manner. 31 In our study, we found miR-146b mimic-transfected M1 cells enhanced wound closure, whereas administration of IL-10 neutralising Ab reversed this effect, suggesting that miR-146b triggered mucosal repair by IL-10 induction. Furthermore, STAT3 is a key target of the IL-10 signalling cascade, so that myeloid cellspecific deletion of STAT3 developed colitis in a manifestation similar to that in IL-10 deficient mice. 47 Lactobacillus reuteri D8 metabolite stimulated lamina propria lymphocytes to secret IL-22 and promoted intestinal epithelial regeneration by STAT3 phosphorylation. 48 In our research, the STAT3 inhibitor Stattic clearly attenuated the effect of recombinant IL-10 on enterocyte wound closure. Taken together, we concluded that miR-146b regulated macrophages to differentiate into M2-like phenotype cells to promote epithelial cell proliferation through STAT3-dependent IL-10 production [ Figure 7 ].
MTC-NP
In summary, with high biocompatibility and security, MTCmiR146b NPs targeted to intestinal macrophages could inhibit M1 activation and the inflammatory response, to promote musical repair and hamper the development of colitis-associated carcinoma after DSS-induced injury. We expect that MTC-miR146b would provide effective anti-inflammatory activity by oral delivery. The modulation of intestinal immune cells by MTC-miR146b would maintain a stable mucosal micro-environment and improve the efficacy of immunotherapies for ulcerative colitis and colon cancer.
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